** Brokerage Jefferies raises its PT for Eli Lilly (LLY.N) to $625 from $615
** The new price target represents a 17.7% upside to the stock’s last close
** LLY’s diabetes medication Mounjaro can achieve about 50% peak market share of all the GLP-1’s in OSA (obstructive sleep apnea)- Jefferies
** GLP-1 drugs, originally developed to help control blood sugar in patients with type 2 diabetes, also suppress appetite and promote a feeling of fullness
** OSA is a disorder strongly associated with obesity where one’s airway passage gets disrupted during sleep
** Including session moves, LLY’s shares up ~47.5% YTD

** Brokerage Jefferies raises its PT for Eli Lillyto $625 from $615

BUZZ-Jefferies raises Eli Lilly PT on potential sales of sleep apnea drug